Back to EZorb Newsletter Index

EZorb

  

EZORB MONTHLY NEWSLETTER DEC 28, 2017

In this issue:

 

1. Share Success: Letters From Readers
2. Research News: Treating RA Effectively May Reduce CVD Risk
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?
  

1. Share Success: Letters From Readers 


Letter I: From T Ryder

Received at Testimonial Submit Form Monday, July 31, 2017 at 19:34:44

(Unedited)

 

Hi, my name is T Ryder. I usually don't give written testimonials, but I remembered that it was the testimonials on your site that prompted me to go ahead and try EZORB.

My podiatrist informed me that the pain I was feeling in my heels was due to bone spurs. They showed me the 'hooks' that was growing out of my heel bone, via x-ray.

I was sent home with a 'boot' to sleep in, and was told to reflex/stretch my ankle while wearing the boot. I was also told that 80% eventually have surgery, because the boot seldom helps; and to get use to the fact that I would eventually end up having surgery on both feet.

While trying out this very uncomfortable 'boot' at night for about a month, I happen to be at a restaurant one evening and saw a gentleman in his 20's hobbling on crutches. I overheard him telling his acquaintance that he had surgery to remove the 1st of his two painful heel spurs.

I immediately went home and looked for a natural solution. I came across EZORB and the testimonials. Took a chance, bought it, and I could tell a decrease in pain in two weeks. I continued for two months and no sign of pain what so ever.

IT WORKS!


Letter II: From Robert

Received at Testimonial Submit Form Friday, July 28, 2017 at 10:31:43

(Unedited)

 

Hi, my name is Robert, and I'm 69.

As of Feb I started having severe pain running from my right buttock down to my right foot. After taking prescription pain pills, blood work, xrays, ultrasound, and a M.R.I. it was decided I have sciatic nerve pain from lower back bone spurs and a touch of arthritis.

With the pain range in the 7-8 range I needed help getting dressed because I couldn't lift my leg, without having searing leg pain.

After seeing a chiropractor with no help there, and having a neurologist telling me I should talk to a back surgeon, I started at the end of May seeing a acupuncturist.

At the same time I found EZorb and started with 4 tsp. a day. After 10 sessions with acupuncture my pain dropped to the 3 pain range. Since my insurance doesn't pay for this service I stopped going.

But I continued with my 4 tsp. of EzORP daily. I can now say happily at the end of July my pain ranges in the zero to one, Ezorp works for me and am ready to order again.

PS I stopped taking the pain pills back around the first of June.


***************************************************

From the Desk of EZorb Newsletter Editor:

 
This newsletter is now read by over 95,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public. If your testimonial is selected for publication, you will receive a gift to show our appreciation of your effort.


2. Research News: Treating RA Effectively May Reduce CVD Risk

 

Targeting factors such as inflammation and disease activity in patients with rheumatoid arthritis (RA) could help reduce their risk for cardiovascular disease (CVD), study findings suggest.

The transatlantic team of researchers found that nearly a third of CVD events were attributable to RA characteristics in the study, which combined information from patients in 10 countries.

Approximately seven in every 10 CVD events were attributable to a combination of all CV risk factors and RA characteristics, the researchers report.

They believe that "the substantial proportion of CVD risk attributable to RA characteristics indicates that RA disease activity and severity play an important role in efforts to reduce CVD risk among patients with RA."

Cynthia Crowson (Mayo Clinic, Rochester, Minnesota, USA) and colleagues studied data on CVD risk factors and RA characteristics from 13 rheumatology centers in Europe, South Africa, the USA, Canada, and Mexico.

The study included 5638 patients with RA and no prior CVD, who had a mean age of 55.3 years and of whom 76% were women. RA-specific factors collected at baseline included rheumatoid factor positivity, anticitrullinated protein antibodies positivity, erythrocyte sedimentation rate (ESR), C-reactive protein, and Disease Activity Score including 28 joints using ESR.

During a mean follow-up of 5.8 years, 148 men and 241 women developed a CVD event, including acute coronary syndrome, chronic ischemic heart disease, coronary revascularization, CVD death, cerebrovascular events, and peripheral vascular events. This gave a 10-year cumulative incidence of 20.9% and 11.1%, respectively.

Men had a significantly higher burden of CVD risk factors than women, including increased blood pressure, increased total cholesterol, and smoking prevalence.

But the relative risks for CVD did not differ between men and women. For both genders smoking and hypertension were the traditional CVD risk factors with the highest population attributable risk (PAR), defined as the proportion of disease that could be prevented by eliminating the risk factor. The next highest PAR was for total cholesterol.

The PARs for Disease Activity Score and for seropositivity were comparable in size to the PAR for lipids.

All the CVD risk factors combined explained 49.0% of the CVD risk in patients, while RA characteristics explained 30.3% of the CVD risk. CVD risk factors and RA characteristics together explained 69.6% of the CVD risk.

Writing in the Annals of Rheumatic Diseases, the researchers conclude: "Knowledge regarding the impact of various risk factors on CVD events is essential to individualize CVD risk evaluation and prevention for patients with RA."

Original article appeared in 18-09-2017 | Rheumatology | News | Article.


3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

  

 

4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ elixirindustry.com for a copy of the instructions.

 

 

5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

 

Back to EZorb Newsletter Index

 
  Copyright 2017 Elixir Industry